Full-Time

Clinical Account Executive

Central CA & Las Vegas, NV

Posted on 11/30/2025

Deadline 12/29/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$91k - $147k/yr

+ Commission + Long-Term Incentive Program

Las Vegas, NV, USA + 2 more

More locations: California, USA | Thousand Oaks, CA, USA

In Person

Field-based role with up to 80% travel; must reside within Central CA or Las Vegas area.

Category
Sales & Account Management (1)
Requirements
  • A minimum of a Bachelor’s degree, OR 4 years of relevant professional/military work experience
  • A minimum of 2 years of clinical or technical work experience in a patient care or hospital environment, OR completion of the Company’s ACAS program
  • Must have a proven track record of building business and increasing market share through commercial execution.
  • Have a valid driver's license issued in the United States
  • Will be required to maintain advanced clinical knowledge of cardiac ablation and cardio imaging, technical knowledge of EP technology, advancements, and the business landscape.
  • Maintain clinical knowledge of healthcare industry, disease states, and therapeutic and institutional trends.
  • The ability to travel related to this role is required. Must be willing and able to travel up to 80% overnight locally, regionally, and nationally, sometimes on short notice.
  • Position requires sitting for extended periods of time, working in a hospital laboratory setting, attending live patient cases, and wearing protective gear (i.e. lead aprons), and willing to work variable hours to meet patient needs
  • May be required to lift up to 60 lbs.
Responsibilities
  • Be an integral part of J&J MedTech Electrophysiology US Field Sales & Service group reporting to the Area Director (AD) and closely partnering with the Program Manager.
  • Focus on increasing market share growth in targeted accounts within a 12-month period.
  • Following the account conversion, the CAE is also responsible for training the local CAS and ensuring a seamless transition at the end of the task.
  • The assignment will require up to 80% travel within the designated Area.
  • Be accountable to provide technical and clinical product support to healthcare providers.
  • This position is expected to achieve key business metrics by flawlessly executing the company's strategies and tactics.
  • Build and maintain mutually beneficial relationships in non-Electrophysiology accounts and for increasing market share of electrophysiology products.
  • The end result should be that Electrophysiology achieves success in the attainment of business objects through the commercial execution and adoption of CARTO® 3 System and other electrophysiology products in the accounts, and that electrophysiology personnel are recognized as best in the industry for their commercial, technicaland clinical competencies.
  • Partners with Territory Managers, Field Service Engineers and Program Manager to ensure alignment and coordination of activities to meet business objectives.
  • At the end of the 12-month assignment, the CAE may find other positions to apply for or potentially may have the option to extend the CAE Assignment for another 12 months (AD approval required).
  • Partner with Marketing and Area Director to develop & execute an account business plan that leads to attainment of business objectives through the commercial execution and adoption of CARTO® 3 System and other electrophysiologyproducts.
  • Accurately assess customer needs, opportunities, and potential barriers, at accounts where CARTO® 3 System is being introduced and establish an adoption plan leading to business growth and sales goal attainment.
  • Provide expert clinical product and technical assistance and training to physicians and EP Lab Staff on the effective use of electrophysiology systems and catheter equipment (e.g., The CARTO® System and appropriate software modules including CARTOMERGE™, CARTOSOUND ™ and the Stockert RF generator) during case procedures within an assigned geography, and in a manner that leads to meeting and exceeding business goals.
  • Educate customers on all electrophysiology products to optimizeeffective usage by providing technical and clinical information and in-service training. Shares best practices to increase value for customers.
  • Use consultative selling techniques to identify potential sales opportunities within the account. Create awareness of electrophysiology solutions and facilitates Territory Sales Manager (TM) contact with the key decision makers to drive incremental business.
  • Maximize customer case support capability through proper planning and scheduling techniques.
  • Drive collaboration and maintain consistent, open lines of communication across the assigned responsibilities with the local team/Pod (i.e. TM and other CAS), as well as the support team (i.e. Ultrasound CAS, FSE, RBD) and other internal and external partners.
  • This position will also develop and share best practices with US Field Sales and Service colleagues and internal partners.
  • Develop and grow mutually beneficial customer relationships within and beyond the EP lab, including, but not limited to physicians, nurses and technicians, clinical and hospital administrators and staff.
  • Stay current on company products instructions for use (IFU), best practices and technical troubleshooting, as well as relevant scientific clinical literature and new product information.
  • Prioritize and appropriately respond to requests in a high-stress environment.
  • Maintain composure and problem-solving focus during stressful interactions.
  • Engage in diagnostic dialogue with multiple internal and external business partners and stakeholders.
  • Formulate solutions based on dialogue and input gained during session. Provide mentoring for new electrophysiologycommercial team members as requested.
  • Respond daily to requests by email and voicemail from customers, practitioners and partners. Perform administrative work, including managing account documentation, compliance training requirements, expense reporting, and Company system input. Maintain Safe Fleet standards according to Company guidelines. Responsible for communicating business related issues or opportunities to next management level. Responsible for ensuring subordinates follow all Company guidelines related to Health, Safety and Environmental practices and that all resources needed to do so are available and in good condition. Responsible for ensuring personal and Company compliance with all Federal, State, local and Company regulations, policies, and procedures.
  • Perform other duties assigned as needed.
Desired Qualifications
  • Electrophysiology/Cath Lab or EP/Cardiovascular Device Industry experience.
  • Maintaining at least one of the following industry certifications – CEPS (IBHRE), RCES/RCIS
  • Experience working with highly complex technical systems and/or working in a critical patient care setting.
  • Effective and timely communicator with co-workers and all levels of patient care team.
  • Self-starter who performs well with autonomy and can be flexible in a dynamic work environment.
  • Problem solver who can think critically in high pressure environments.
  • Receptive to constructive feedback and collaborates and works well in team environment.
  • Able to take large amounts of data and translate information into actionable insights
  • Hunger for learning and building new skills

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Icotyde launches with 1,500 prescriptions, Guggenheim projects $14.9 billion peak sales.
  • Atraverse Medical acquisition bolsters HOTWIRE system for atrial fibrillation ablations.
  • ETHICON 4000 Stapler gains CE Mark, reducing surgical leaks costing €5,200 per case.

What critics are saying

  • Stelara sales plummet 60% to $656 million from Amgen and Samsung biosimilars.
  • Over 90,000 talc lawsuits trigger $966 million October 2025 verdict against J&J.
  • CARVYKTI manufacturing shortfalls cap multiple myeloma sales growth in 2026.

What makes Johnson & Johnson unique

  • Diversified revenue spans Innovative Medicine, MedTech, and consumer health segments.
  • DARZALEX sales hit $4 billion in Q1 2026, exceeding forecasts by $600 million.
  • CARTO System marks 30 years, powering AI-driven CARTOSOUND SONATA for electrophysiology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE